NCT03087097终止1 期
Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema (THRIVE) for Patients in the Rehabilitative Phase of Malnutrition: A Pilot Study Evaluating Microbial Engraftment, Safety and Nutritional Outcomes
Microbiome Health Research Institute1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2019年4月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Serious Adverse Events
研究概览
简要总结
This single-center, randomized, open-label trial will compare the safety of MTT delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (moderate acute malnutrition [MAM] or severe acute malnutrition [SAM]) who are in the rehabilitative phase of treatment and have failed to respond to at least 4 weeks of standard therapy. Participants must meet inclusion criteria, no exclusion criteria prior to randomization. Participants will then be randomized in a 1:1 ratio at each site to 1 of 2 treatment groups:
- MTT by rectal catheter enema: 10mL/kg (maximum 150mL, +/- 5ml) of healthy donor human intestinal microbiota will be infused.
- Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines Participants will be evaluated through 56 days (±3) after randomization for primary outcomes (safety) as well as secondary outcomes (nutritional, clinical and microbiological response).
Participant blood and urine samples will be collected at enrollment and day 56. Participant stool samples will be collected at enrollment and through days 3, 7, 21 and 56, thereafter, 3 months, 4 months, and 6 months. A caregiver stool sample will be collected at enrollment and day 56. Samples will be used for microbiome determination and other exploratory microbiological endpoints. An aliquot of donor stool will also be stored for microbiome determination and other exploratory microbiological endpoints and assessment of newly acquired infectious agents.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 12 Months 至 60 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant Inclusion Criteria
- •Participants eligible to participate in this study must meet the following inclusion criteria:
- •Age 12 to 60 months.
- •Current diagnosis of malnutrition (defined as a WHZ less than -2 according to the WHO 2006 standards or a MUAC less than 125mm) with failure to respond nutritionally, defined as:
- •a. A WHZ of less than -2 according or a mid-upper-arm circumference of less than 125 mm i. No medical complications present ii. Participant is sufficiently alert and successfully passes the appetite test which involves consumption of breastmilk or a ready to use therapeutic food (RUTF) under supervision.
- •iii. Participant is in the rehabilitation phase of treatment for malnutrition
- •HIV negative
- •Received at last four weeks of optimal WHO treatment for malnutrition:
- •Micronutrient supplementation (Vitamin A, zinc and iron) as recommended by local guidelines
- •Nutritional rehabilitation as recommended by local guidelines.
- •Written informed consent obtained by parent or caregiver.
- •Participant
排除标准
- •Participants will not be able to participate if they meet any of the following exclusion criteria:
- •Evidence of current complicated malnutrition defined as any of the following:
- •Admitted to acute care ward as inpatient
- •Signs of severe acute infection such as pneumonia, bacteremia, meningitis. Minor infections such as candida dermatitis, pharyngitis, upper respiratory tract infections will be eligible for inclusion at the discretion of the study physician.
- •One or more WHO Integrated Management of Childhood Illness danger signs.(3)
- •Failure to pass appetite test.
- •Presence of known comorbid diseases such as pulmonary Tuberculosis on treatment, cystic fibrosis, type I diabetes mellitus, intestinal malabsorptive syndromes, chronic lung disease, chronic liver disease, chronic renal disease, chronic neurological diseases (e.g. cerebral palsy) or malignancy undergoing active chemotherapy.
- •Bilateral pitting pedal edema or generalized anasarca
- •Have taken antibiotics in the past seven days before the Day 0 visit or are anticipated to need antibiotics up to seven days before the Day 0 visit.
- •Congenital malformations, syndromic conditions, and congenital metabolic abnormalities (inborn errors of metabolism) that may adversely affect growth and in the view of the clinician, exposes the child to increased risk.
- •a. Fetal alcohol syndrome (FAS) is not an exclusion.
- •Presence of bilateral pitting edema Grade
- •Contraindications to rectal catheter enema:
- •Anorectal malformations
- •Rectal prolapse
- •Hirschsprungs disease
- •Other contraindication to enema.
- •Primary immune deficiencies
- •Acute, persistent or chronic diarrhea.
- •Intestinal abnormalities including malformations, Hirschsprungs disease and short bowel syndrome
- •Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines puts the participant at greater risk from MTT
结局指标
主要结局
Serious Adverse Events
时间窗: 56 days
Number of participants with an Adverse Event grade 2 or above up to 56 days post-treatment
次要结局
- Nutritional recovery:(56 days)
- Microbiological:(56 Days)
- Translational:(56 Days)
- Clinical:(56 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Randomised Placebo-controlled Study of FMT to Impact Body Weight and Glycemic Control in Obese Subjects With T2DMType2 DiabetesObeseType 2 Diabetes MellitusNCT03127696Chinese University of Hong Kong61
已完成
2 期
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile InfectionClostridia Difficile ColitisClostridium Difficile DiarrheaNCT03806803University of Alberta138
已完成
2 期
FMT in IT-refractory HCC - FAB-HCC Pilot StudyHepatocellular CarcinomaNCT05750030Medical University of Vienna12
已完成
早期 1 期
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic MesotheliomaMesotheliomaNCT04056026ProgenaBiome1
已完成
1 期
Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.Sclerosing CholangitisNCT02424175Brigham and Women's Hospital10